NTLA - Intellia Therapeutics, Inc.

8.31
0.130   1.564%

Share volume: 1,946,473
Last Updated: 04-25-2025
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances: 0.03%

PREVIOUS CLOSE
CHG
CHG%
$8.18
0.13
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
40%
Profitability 25%
Dept financing 30%
Liquidity 50%
Performance 55%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.72%
1 Month
2.97%
3 Months
-16.98%
6 Months
-49.14%
1 Year
-62.19%
2 Year
-77.99%
Key data
Stock price
$8.31
P/E Ratio 
0.00
DAY RANGE
$7.91 - $8.33
EPS 
-$4.03
52 WEEK RANGE
$5.90 - $28.18
52 WEEK CHANGE
-$62.19
MARKET CAP 
1.188 B
YIELD 
N/A
SHARES OUTSTANDING 
101.579 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
2.97
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,898,379
AVERAGE 30 VOLUME 
$3,723,583
Company detail
CEO: John M. Leonard
Region: US
Website: intelliatx.com
Employees: 600
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis. The firm has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells.

Recent news
loading